There is emerging evidence that the oncogenic potential of hdm2 (human and/or murine double minute-2 protein) stems not only from its ability to counteract tumor suppressor p53 but also from its less understood p53-independent functions. Surprisingly, little is known about the role and regulation of hdm2 in pancreatic tumors, a large proportion (50-75%) of which contain mutant p53. In this study, we determined that hdm2 was expressed in a Ras-signaling-dependent manner in various pancreatic cancer cell lines. As p53 was mutated and inactive in these cells, the expression of hdm2 was seemingly redundant. Indeed, the proliferation and survival of cell lines such as Panc-1 and Panc-28 could be inhibited by PRIMA-1 (mutant p53 activator) but not by Nutlin-3 (inhibitor of the hdm2-p53 interaction). Unexpectedly, however, the proliferation of both cell lines was strongly inhibited by hdm2-specific RNAi. Our data also revealed cyclin D1, c-Jun and c-Myc to be novel targets of hdm2 and suggested that they might mediate hdm2's role in cellular proliferation and/or survival. We conclude from our results that hdm2 is expressed in pancreatic cancer cells as a result of activated Ras signaling, and that it regulates cellular proliferation and the expression of three novel target genes by p53-independent mechanisms.
Introduction
The hdm2 (human and/or murine double minute-2 protein) gene product is pivotal to the regulation of p53, a tumor suppressor protein that induces cell-cycle arrest or apoptotic cell death in response to specific stress stimuli, and whose genetic alterations are common in human cancers such as pancreatic ductal adenocarcinoma or PDAC (Deb, 2003; Iwakuma and Lozano, 2003; Hezel et al., 2006) . Oncogenic or genotoxic stress signals induce p53, which then triggers an exquisitely regulated feedback loop by transactivating the hdm2 promoter. Once synthesized, hdm2 not only binds to p53 and represses its transcriptional activity but can also act as an E3 ubiquitin ligase that targets p53 for nuclear export or proteasomal degradation (Freedman et al., 1999; Deb, 2003) . As a result of hdm2's action, p53 is restrained in non-stressed cells or eliminated after the successful completion of DNA repair, thereby allowing cells to survive and proliferate (Freedman et al., 1999; Deb, 2003) . Recent evidence suggests, however, that hdm2 might first influence the biological outcome of p53 function before degrading it (Shmueli and Oren, 2007) .
There is strong experimental evidence that hdm2 possesses p53-independent activities as well (Daujat et al., 2001; Ganguli and Wasylyk, 2003) , activities that might promote tumorigenesis in cooperation with other aberrant genes (Deb, 2003) . Indeed, rare but aggressive tumors containing inactivating p53 mutations also overexpress hdm2, and when hdm2 was ectopically overexpressed in the mice mammary epithelium, it conferred tumor-like phenotypes even in the absence of p53 (Lundgren et al., 1997) . In addition, hdm2 was observed to confer resistance to transforming growth factor-b1 in a p53-independent manner (Sun et al., 1998) , and hdm2 splice variants lacking portions of the p53-binding domain and possessing transforming activities were found in human tumors (Sigalas et al., 1996; Fridman et al., 2003; Steinman et al., 2004; Harris, 2005) . Furthermore, there was a higher incidence of sarcomas in transgenic mice overexpressing hdm2 than in p53-null mice, and these tumors developed even when p53 was absent (Jones et al., 1998) . Although their molecular basis is still poorly understood, the p53-independent functions of hdm2 could be important for the development of PDACs and other cancers that express mutant p53.
Similar to the function of hdm2, the overexpression of hdm2 in tumors is not always dependent on p53 (Deb, 2003) . In one such instance, a single nucleotide polymorphism results in enhanced affinity for the transcription factor Sp1 within the hdm2 promoter, which increases hdm2 expression (Bond et al., 2004) . Specific growth factor-and oncogene-inducible signaling pathways also increase hdm2 expression, but through other p53-independent mechanisms (LevavCohen et al., 2005) . In the case of PDACs, which typically harbor oncogenic K-Ras and overexpress a variety of ligand-receptor systems (Hezel et al., 2006) , little is known about hdm2 and its function. In this study, we determined that hdm2 is expressed in pancreatic cancer cells because of the Ras-Raf-MEK (mitogen and extracellular signal-regulated protein kinase) signaling pathway and that it regulates cellular proliferation and the expression of three proteins not known earlier to be its targets, c-Jun, c-Myc, and cyclin D1, by p53-independent mechanisms.
Results
Hdm2 is expressed at high levels in pancreatic cancer cell lines containing activated K-Ras and mutant p53 We investigated hdm2 expression in various pancreatic cell lines. Two different bands that might represent known splice variants of hdm2 (Bartel et al., 2002) were observed. Our data indicate that pancreatic cancer cell lines, with the exception of BxPC-3, expressed hdm2 at significantly higher levels than the human pancreatic duct epithelial cells (HPDE-E6E7) (Figure 1a ). p53 also appeared to be overexpressed in the same pancreatic cancer cells as hdm2. This was probably because the cancer cells, unlike HPDE-E6E7 cells (Ouyang et al., 2000) , contain mutant p53 (Brunner et al., 2005 ; Panc-28 cells, data not shown), which tends to be more stable than the wild-type protein (Jackson et al., 2003) . The expression of hdm2 in cell lines other than HPDE-E6E7 and Panc-1 cells appeared mostly constitutive and independent of serum factors ( Figure 1a) . As reported earlier for other cell types (Shaulian et al., 1997; Bai and Cederbaum, 2006) , an inverse relationship between the expression of p53 and hdm2 was observed but only in HPDE-E6E7 cells (Figure 1a ). These results suggest that hdm2 is expressed in pancreatic cancer cells that contain inactivating p53 mutations and constitutively active K-Ras.
Hdm2 expression is dependent on the Ras-Raf-MEK signaling pathway We observed a causal link between oncogenic K-Ras and hdm2 expressions in pancreatic cancer cells (Figure 1a) . Indeed, whereas cells with wild-type KRas expressed low levels of hdm2 (BxPC-3 and HPDE-E6E7), cells with oncogenic K-Ras expressed higher levels of hdm2 (that is, Panc-1, Panc-28, Panc-48, AsPC-1, Capan-1, and MiaPaCa-2 cells). To investigate this further, we first performed Raf1 GST-RBD (GST fused to the Ras-binding domain of Raf1) pulldown assays to determine the activation status of K-Ras in three cell lines. Although K-Ras is wild type in BxPC-3 cells (Brunner et al., 2005) , it contains oncogenic mutations (codon 12) in Panc-1 (Brunner et al., 2005) and Panc-28 cells (data not shown). The pulldown assays suggested that K-Ras was indeed activated in Panc-1 and Panc-28 cells, but not in BxPC-3 cells (Figure 1b) . When Panc-1 and Panc-28 cells were treated with FTS (S-trans, trans-farnesylthiosalicylic acid), a compound that inhibits Ras by dislodging it from the plasma membrane and which has been shown to inhibit pancreatic tumor growth (Weisz et al., 1999) , the amount of activated K-Ras that could be pulled down by GST-RBD, but not total cellular K-Ras, was decreased (Figure 1b ). In addition, FTS was able to inhibit (>80%) the expression of hdm2 within approximately 3 h of treatment ( Figure 1c ). FTS had little or no effect on p53 expression, suggesting that its effects on hdm2 were specific and, as noted earlier, that p53 was probably not under any hdm2 control in pancreatic cancer cells.
We further observed that an hdm2 P2 promoter luciferase reporter gene containing Ras-responsive (Ries et al., 2000) elements was strongly induced when transfected into Panc-28 cells (Figure 1d ). The overexpression of activated K-Ras or p53 strongly increased reporter expression, thereby confirming that the reporter was indeed Ras-and p53-inducible. In contrast, K-Ras short hairpin RNA inhibited the reporter activity, indicating that activated K-Ras was essential for the induction of the P2 promoter in these cells.
Consistent with the involvement of the Ras-Raf-MEK pathway, a Raf inhibitor (GW5074) and a MEK inhibitor (CI-1040) inhibited ERK (extracellular signalregulated kinase)/MAP kinase phosphorylation and reduced endogenous hdm2 expression in Panc-28 cells (Figure 2a ). In contrast, CI-1040 had no effect on the low but detectable levels of hdm2 in wild-type K-Rascontaining BxPC-3 cells (Supplementary Figure S1A) . The knockdown of MEK1/2 also sufficed to reduce endogenous hdm2 levels ( Figure 2b ). Consistent with our earlier study (Asano et al., 2004) , these data further suggested that MEK was also essential for the expression of c-Myc and cyclin D1 in pancreatic cancer cells (Figure 2b ).
Hdm2 has an essential p53-independent function in pancreatic cancer cell proliferation and/or viability We used two different inhibitors (Nutlin-3 and PRIMA-1) in a complementary approach to analyse p53 and hdm2 activities in pancreatic cancer cells. As Nutlin-3 is a small-molecule antagonist of hdm2 that specifically disrupts its protein-protein interactions with p53 (Vassilev et al., 2004) , we reasoned that even if hdm2-p53 interactions were disrupted by this inhibitor, the proliferation or survival of pancreatic cancer cells would not be affected by the liberated, but functionally deficient, p53. Indeed, the proliferation of both Panc-1 and Panc-28 cells was only marginally inhibited by 1-8 mM Nutlin-3 ( Figure 3a ). As this concentration range has been shown earlier to inhibit a wide range of cell lines that possess wild-type p53, our data confirm that p53 is indeed inactive in Panc-1 and Panc-28 cells. In contrast, Nutlin-3 was able to strongly inhibit the Hdm2 in pancreatic cancer cells X Sui et al proliferation of wild-type p53-expressing Capan-2 pancreatic cancer cells (Figure 3a) . Although Capan-2 cells express hdm2 at low levels comparable with those in BxPC-3, their p53 levels were barely detectable (Supplementary Figure S1B ). Consistent with the effect of Nutlin-3, a second inhibitor (PRIMA-1), which binds to mutant or functionally inactive p53 and restores its biological activity (Bykov et al., 2002) , was potently able to inhibit the proliferation of Panc-1 and Panc-28 cells but also that of Capan-2 cells (Figure 3a ). Trypan blue exclusion assays indicated that apoptosis was indeed involved in the effect of Nutlin-3 on Capan-2 cells and in the effect of PRIMA-1 in all three cell lines ( Figure 3b ). As activated K-Ras and mutant p53 coexist in the pancreatic cancer cell lines we examined, it is conceivable that K-Ras-induced hdm2 has p53-independent functions. To test this intriguing possibility, we designed and tested small-interfering RNA (siRNA) for the P a n c -1 P a n c -2 8 P a n c -4 8 A s P C -1 M i a P a C a -2 B x P C -3 C a p a n -1 kDa 100 
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x P C -3 P a n c -2 8 P a n c -1 (ii) Figure 1 Hdm2 is overexpressed in pancreatic cancer cell lines in a Ras-dependent manner. (a) Immortalized human pancreatic duct epithelial cells (HPDE-E6E7) and various pancreatic cancer cell lines were cultured in the presence ( þ ) or absence (À) of growth factor/serum-containing media. Whole-cell lysates (WCEs) were prepared and analysed by immunoblotting for hdm2, p53 and actin. The molecular weight markers (in kDa) are indicated for the hdm2 blot. (b) Serum-starved pancreatic cancer cell lines were treated for 2 h with or without the Ras antagonist FTS (S-trans, trans-farnesylthiosalicylic acid; 30 mM). WCEs were prepared and either incubated with GST-RBD (GST fused to the Ras-binding domain of Raf1), which binds to activated Ras (GST-RBD assay), or directly probed for total cellular K-Ras. GST-RBD-bound protein was first eluted before analysis by western blotting for K-Ras. (c) Panc-1 and/or Panc-28 cells were treated with various concentrations of FTS for 3 h (i) or with 30 mM FTS for the indicated time points (ii). WCEs were analysed for hdm2, p53 and b-actin. (d) We used hdm2 (P2) promoter-luciferase reporter constructs with (L1/luc) or without (L6/ luc) AP-1 and Ets-binding sites. Both L1 and L6 have been described earlier (Ries et al., 2000) . A control reporter (pCMV-LacZ) or L1/luc was co-transfected into Panc-28 cells (12-well plates) with activated K-Ras (K-Ras G12D ), oncogenic K-Ras G12D shRNA (short hairpin RNA) or a p53 expression vector using Lipofectamine (Invitrogen). The DNA concentration was kept equal in all transfections (0.6 mg) using either pSUPER or pCMV-FLAG2 vector. Cells were also transfected with L6/luc or the pGL3-basic vector as controls. After 36-48 h, cells were lysed and assayed for luciferase activity as described elsewhere (Asano et al., 2004) . All values were obtained in triplicate and normalized to the b-galactosidase activity determined with the Galacto-Light Plus kit (Tropix, Bedford, MA, USA).
Hdm2 in pancreatic cancer cells X Sui et al knockdown of endogenous hdm2 ( Figure 4 ) and investigated whether it had any role in the proliferation of Panc-1 and Panc-28 cells. In addition to a nontargeting control siRNA, we used siRNA against two different targeting sequences of hdm2. Both hdm2 siRNAs strongly inhibited Panc-1 and Panc-28 cells, indicating that hdm2 was, in fact, essential for their proliferation. As p53 is mutated in these cells and Nutlin-3 had no effect, these data suggest that hdm2 regulated their proliferation independent of p53 ( Figure 4) . Consistent with the effect of Nutlin-3, and the fact that they contain wild-type p53, the proliferation of Capan-2 cells was also inhibited by knocking down hdm2 (Figure 4 ).
Hdm2 mediates a novel p53-independent mechanism to regulate the expressions of cyclin D1, c-Jun and c-Myc in pancreatic cancer cells To investigate the molecular basis of hdm2-dependent cell proliferation, we analysed the effect of its knockdown using the two different hdm2 siRNAs on the expression of specific proteins known to be involved in cell proliferation and/or survival in pancreatic cancer cells. To our surprise, we found that hdm2 was specifically required for the expressions of cyclin D1, c-Myc and c-Jun but not for Akt, p53, the EGF (epidermal growth factor) receptor (EGFR) or actin ( Figure 5a ). As MEK siRNA ( Figure 3c ) and its antagonist PD098059 (Asano et al., 2004 ) also inhibited the expressions of both c-Myc and cyclin D1, these data link both proteins to hdm2 through the Ras-Raf-MEK signaling. p53 involvement is ruled out because it is functionally inactive in these cells, with neither Nutlin-3 nor PRIMA-1 having any effect on the three proteins (Figure 5a ). Moreover, although p53 siRNA was able to reduce the p53 levels by over 80%, it did not affect the expressions of cyclin D1, c-Jun and c-Myc (Figure 5b ). Similar to FTS, hdm2 siRNA also did not alter p53 expression levels, indicating that p53 was not subject to hdm2-mediated degradation in pancreatic cancer cells. Conversely, p53 siRNA did not affect hdm2 expression either, consistent with its being mutated and with our data implicating the Ras-Raf-MEK signaling as being responsible for hdm2 expression in these cells. When hdm2 was overexpressed in HPDE-E6E7 cells, there was a significant increase in the expression levels of c-Jun and cyclin D1 (Figure 5c ).
Although hdm2 is primarily known to ubiquitinate proteins such as p53 and to facilitate their degradation, it has also been reported recently to stabilize E2F1 by preventing its ubiquitination (Zhang et al., 2005) . Our results suggest that hdm2 might be required for the stabilization of cyclin D1, c-Jun and c-Myc proteins as well. To evaluate this possibility, we first tested whether hdm2 knockdown was indeed affecting protein ubiquitination, as is to be expected. We observed that, in the absence of the proteasome inhibitor MG-132, protein ubiquitination levels were abundant and that hdm2 knockdown did not appear to lower them (Supplementary Figure S1C ). In sharp contrast, numerous ubiquitinated proteins could be easily visualized when MG-132 was included in the treatment, presumably due to the blockage of downstream proteasomal action (Supplementary Figure S1C ). Many of these proteins could not be detected when hdm2 expression, and therefore its E3 ubiquitin ligase activity, was knocked down by RNAi. Thus, hdm2 knockdown clearly altered the ubiquitination of various proteins in pancreatic cancer cells and MG-132 efficiently blocked their proteasomal degradation. We reasoned that if cyclin D1, c-Myc and c-Jun are actually stabilized by hdm2 through a mechanism that protects them from proteasomal degradation, then MG-132 would be able to prevent their loss of expression in cells with hdm2 knock down. MG-132 treatment increased the expression levels of hdm2 (see especially upper band *), c-Jun, cyclin D1 and c-Myc consistent with the notion that all four proteins are regulated by proteasomal degradation. As observed earlier in the absence of MG-132, the knocking down of hdm2 once again reduced the expression of all three proteins in pancreatic cancer cells (Figure 5d ). However, to our surprise, the presence of MG-132 did not prevent the loss of expressions of cyclin D1, c-Myc and c-Jun due to hdm2 knockdown (Figure 5d ). These data suggest therefore that hdm2 regulates the expressions of cyclin D1, c-Myc and c-Jun by a mechanism that does not directly involve their proteasomal degradation.
We did not find any hdm2-mediated changes in the subcellular localization of these proteins, nor evidence for proteasome-independent degradation (data not shown), suggesting that other mechanisms are involved. Indeed, quantitative PCR indicated that hdm2 might in fact regulate their transcript levels because the mRNA expression of all three genes was strongly inhibited in pancreatic cancer cells transfected with hdm2 siRNA (Figure 6a ). Interestingly, Panc-28 cells expressing HA-c-Jun were significantly more viable (66%) than control cells (27%) after hdm2 knockdown (Figure 6b ). These data suggest that c-Jun is capable of protecting cells from the effects of hdm2 knockdown and that it might mediate hdm2 function in cellular proliferation and/or survival along with c-Myc and cyclin D1.
Discussion
In this study, we determined that hdm2 was expressed at higher levels in pancreatic cancer cell lines than in HPDE-E6E7 cells because of the Ras-Raf-MEK signaling. Whereas one study (Ruggeri et al., 1997) has shown that hdm2 was not amplified and might not be overexpressed, others have shown hdm2 to be overexpressed in a large proportion of PDACs (Ebert et al., 1994) . Although the reason for this discrepancy is not understood, it is conceivable that hdm2 is overexpressed in cancers that contain activating K-Ras mutations. 
Panc-28
Panc-1 Figure 4 Hdm2 has a p53-independent function in pancreatic cancer cells with mutant p53. Two different hdm2-targeting siRNAs were designed and transfected into three pancreatic cancer cell lines to test their effects on proliferation and hdm2 expression. Nontargeting siRNA was used a control. Panc-1, Panc-28 and Capan-2 cells were transfected either with 50 or 75 nM of the two different hdm2 siRNAs. At the indicated time points, cells were stained with crystal violet dye before the absorbance at 540 nm was determined. Whole-cell lysates were prepared and analysed by western blotting for hdm2 and actin expressions.
As p53 was mutated in the pancreatic cancer cells and its knockdown by RNAi did not alter hdm2 levels, our results indicate that it was dispensable for Ras-induced hdm2 expression. These data strongly support a study by Reis et al., who showed that the Ras-Raf-MEK signaling increased hdm2 expression in NIH 3T3 cells by inducing its P2 promoter. The fact that MEK might also regulate the export of hdm2 mRNA to the cytoplasm was reported by Blaydes and co-workers (Phelps et al., 2005) . They subsequently suggested that both constitutive hdm2 expression in breast cancer cells involving transcription from the P2 promoter and serum-inducible Cells were harvested 48 h later. Total RNA was prepared and reverse transcribed using random hexamers and AMV RT (Promega). Quantitative PCR (qPCR) was performed as described in Materials and methods to amplify fragments of c-Jun, c-Myc and cyclin D1. The Biorad iCycler data analysis software was used to calculate C t values, and relative gene expression was determined using the formula 2 ðÀDCtÞ ¼ 2 ðÀCtðactinÞÀCtðtargetÞÞ , which reflected target gene expression normalized to GAPDH or b-actin levels and was given an arbitrary number of 1 for the control siRNA-treated samples. For the comparative C t method to be valid, serial dilutions of total RNA samples were used for reverse transcription-PCR amplification to confirm that the amplification efficiencies of the target and control genes were similar. These results are reflective of two independent experiments, each of which was performed in triplicate.
Hdm2 in pancreatic cancer cells X Sui et al hdm2 expression in human fibroblasts involving protein stabilization might involve signaling pathways other than Ras-Raf-MEK (Phelps et al., 2003; Phillips et al., 2006) . There is evidence that the phosphoinositide 3-kinase (PI3-kinase) cascade is one such pathway, with a vital role in hdm2 stabilization and anti-apoptotic function (Levav-Cohen et al., 2005) . As it is activated in pancreatic cancer cells (Asano et al., 2004) , this pathway might cooperate with Ras to regulate hdm2 function. Whether hdm2 expression in PDACs is also regulated by additional mechanisms such as alternative/aberrant splicing remains to be determined (Bartel et al., 2002; Iwakuma and Lozano, 2003) .
Surprisingly, mutant p53 appeared to be protected from hdm2-mediated degradation in pancreatic cancer cells because neither the Ras inhibitor FTS nor hdm2 siRNA was able to elevate its levels despite they being able to reduce hdm2 expression. Mechanisms that ordinarily protect wild-type p53 from the action of hdm2 involve changes such as those in the phosphorylation status, subcellular localization or proteinprotein interactions of one or both molecules (Prives and Hall, 1999; Peng et al., 2001) . It is interesting to speculate that one of these mechanisms also facilitates the p53-independent function of hdm2 or any gain of function of mutant p53 in pancreatic cancer cells.
The fact that PRIMA-1 could inhibit pancreatic cancer cells with wild-type p53 such as Capan-2 was somewhat unexpected but was recently observed in another cell type to trigger p53-specific transcriptionindependent apoptosis (Chipuk et al., 2003) . More intriguingly, two different hdm2-specific siRNAs inhibited the proliferation of Panc-1 and Panc-28 cells. As both cell lines contain mutant p53 and were resistant to Nutlin-3, these data indicate that their proliferation is regulated by hdm2 independent of p53. Hdm2 might also promote the resistance of pancreatic cancer cells to both radiation and drugs (Agrawal et al., 2001; Zhang et al., 2004) .
Although there is strong evidence that hdm2 has p53-independent functions in cancer, the molecular underpinnings of these functions are poorly understood (Daujat et al., 2001) . Our data indicate that hdm2 regulates the constitutive expressions of c-Jun, c-Myc and cyclin D1, proteins not known earlier to be its targets. As their expression was not reduced by Nutlin-3, PRIMA-1 and p53 knockdown, a p53-independent function of hdm2 is likely involved in their regulation. In were generated and transfected with control or hdm2 siRNA (hdm2-1881). After 48 h, cells were either lysed for western blotting analyses (a) or counted after trypan blue staining (b). Cells were counted in triplicates and the data presented here (mean ± s.e.m.) are reflective of three independent experiments. The ability of c-Jun to protect Panc-28 cells from the effect of hdm2 knockdown was found to be statistically significant (*Po0.05).
Hdm2 in pancreatic cancer cells
X Sui et al fact, these data indicated that p53 does not antagonize any of the three proteins either as reported in other cell types (Frazier et al., 1998; Schreiber et al., 1999; Rocha et al., 2003; Ho et al., 2005) . As c-Myc, cyclin D1 and c-Jun have all been strongly implicated in proliferation, survival and tumorigenesis, it is conceivable that they mediate the p53-independent function of hdm2 in the proliferation of pancreatic cancer cells. Consistent with this possibility, we observed that overexpression of the c-Myc mutant Mad-Myc (Asano et al., 2004) or the c-Jun mutant TAM67 (data not shown) inhibited the proliferation of pancreatic cancer cells, and that exogenous c-Jun is significantly capable of protecting cells from the anti-proliferative effect of hdm2 knockdown (this study).
We speculate that the p53-independent function of hdm2 involves its interactions with molecules such as the L5 ribosomal protein and 5S rRNA, the retinoblastoma gene product Rb and transcription factors such as E2F, TATA box binding protein (TBP) and TAF II 250, MyoD, hypoxia-inducible factor-1 (HIF-1) and Sp1 (Freedman et al., 1999; Daujat et al., 2001; Deb, 2003; Ganguli and Wasylyk, 2003) . Hdm2 also interacts with the p53-related proteins p63 and p73 but without degrading them (Iwakuma and Lozano, 2003) . Of these, Nutlin-3 might block the interactions of hdm2 with HIF-1 and E2F1 (Ambrosini et al., 2007; LaRusch et al., 2007) . Although Nutlin-3 did not appear to inhibit the p53-independent function of hdm2 in our studies, we cannot yet rule out HIF-1 or E2F1 as potential hdm2 mediators in pancreatic cancer cells. Our data indicate that hdm2 regulates the mRNA levels of cyclin D1, cMyc and c-Jun but not their protein stability. The fact that hdm2 influences the transcription of all three targets through one or more of these interacting proteins or by negatively influencing ERK/MAP kinase (Carroll and Ashcroft, 2008) is an exciting possibility that we are currently investigating.
We have provided what is to our knowledge the first evidence that hdm2 is expressed in pancreatic cancer cells because of the Ras-Raf-MEK signaling pathway and that hdm2 regulates cellular proliferation and the expression of three proteins not known earlier to be its targets (c-Jun, c-Myc and cyclin D1) by p53-independent mechanisms. The ability of hdm2 to be upregulated by a variety of mechanisms and to mediate p53-independent oncogenic effects could be a reflection of its more pervasive role in tumorigenesis than has currently been believed.
Materials and methods

Cell lines and antibodies
AsPC-1, BxPC-3, Capan-1, Capan-2, MiaPaCa-2 and Panc-1 cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured according to standard methods. Panc-3, Panc-28, and Panc-48 cells were a generous gift from Dr Paul Chiao (M.D. Anderson Cancer Center, Houston, TX, USA) and were maintained in RPMI 1640 supplemented with 10% fetal bovine serum under standard culture conditions. Human pancreatic duct epithelial cells (HPDE-E6E7) (a generous gift from Dr Ming-Sound Tsao, Ontario Cancer Institute, Toronto, ON, Canada) were cultured as described elsewhere (Ouyang et al., 2000) . We purchased the p53, K-Ras, ERK, c-Myc, cyclin D1, EGFR, Akt1/2 and phospho-ERK (Santa Cruz Biotechnology, Santa Cruz, CA, USA); MEK1/2, c-Jun and ubiquitin (Cell Signaling Technology, Beverly, MA, USA); ERK (BD Transduction Laboratories, San Diego, CA, USA); b-actin and hdm2 (Sigma, St Louis, MO, USA) antibodies. The Ras (FTS) and Raf (GW5074) inhibitors were purchased from Sigma, and Nutlin-3 and PRIMA-1 from Cayman Chemical (Ann Arbor, MI, USA). CI-1040 (PD184352) was a generous gift from Pfizer (Cambridge, MA, USA).
Cell lysate preparation and immunoblotting Whole-cell extracts (WCEs) were prepared for immunoblotting as described elsewhere (Asano et al., 2004) . Briefly, cells were lysed in buffer containing 50 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.5, 1.5 mM MgCl 2 , 150 mM NaCl, 1 mM EGTA (ethylene glycol bis (b-aminoethylether)-N,N,N 0 ,N 0 ,-tetraacetic acid), 20 mM NaF, 10 mM Na 4 P 2 O 7 (sodium pyrophosphate), 10% glycerol, 1% Triton X-100, 3 mM benzamidine, 1 mM Na 3 VO 4 (sodium orthovanadate), 1 mM pepstatin, 2 mg/ml aprotinin and 2 mg/ml leupeptin. WCEs were clarified by centrifugation at 14 000 Â g for 5 min, and proteins were probed by western blotting using electrochemiluminescence (GE Healthcare, Piscataway, NJ, USA).
Construction of pCMV-FLAG2-K-Ras
G12D
Full-length K-Ras (K-Ras G12D ) was isolated by reverse transcription-PCR (Titan One Tube RT-PCR kit; Roche, Indianapolis, IN, USA) from total RNA that was extracted from AsPC-1 pancreatic cancer cells using the following primers (forward: 5 0 -GCGCAAGCTTGGCCTGCTGCAAA TGACTG-3 0 , reverse: 5 0 -GCGCGTCGACCCACTTGTAC TAGTATGCC-3 0 ). The PCR product was then cloned inframe into the HindIII and SalI sites of the pCMV-FLAG2 expression vector (Sigma) using standard protocols and sequenced.
Serum starvation and inhibitor treatment HPDE-E6E7 or pancreatic cancer cells in 10 cm dishes (7 Â 10 5 cells per dish) were either left in the EGF-(HPDE-E6E7) or serum-containing (pancreatic cancer cells) medium or serumstarved overnight (16 h), and later cells were harvested to examine hdm2 and p53 protein expressions in cell lysates. Where necessary, serum-starved cells were cultured further but in the presence or absence of an inhibitor (FTS, GW5074 or CI-1040). Nutlin-3 and PRIMA-1 were added to cells (5 Â 10 5 cells per 6 cm dish) in the presence of serum for a total of 48 h. siRNAs, short hairpin RNA and transfection Five different target sequences were identified in hdm2 using the Ambion siRNA Target Finder (http://www.ambion.com/ techlib/misc/siRNA_finder.html). siRNAs were then designed, synthesized (siRNA Construction Kit; Ambion, Austin, TX, USA) and tested for their ability to knock down hdm2. Two of the five siRNAs (hdm2-856: AACGCCACAAATCTGATA GTA and hdm2-1881: AATGCCTCAATTCACATAGAT) were able to knock down >80% of cellular hdm2 expression and were therefore selected for this study. Control nontargeting siRNA was purchased from Ambion. siRNAs for the knockdown of p53 and MEK1/2 have been described earlier (Natsume et al., 2005; Lee et al., 2006) and were synthesized at Hdm2 in pancreatic cancer cells X Sui et al Sigma-Genosys (The Woodlands, TX, USA). Oncogenic K-Ras (G12D) short hairpin RNA was constructed using the pSUPER vector (Oligoengine, Seattle, WA, USA) as described elsewhere (Brummelkamp et al., 2002) .
Panc-28 cells (5 Â 10 5 per 6 cm dish) were transfected with control (100 nM), hdm2 (50-75 nM), MEK (50 nM MEK1 þ 50 nM MEK2) or p53 (100 nM) siRNAs with the Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA). Medium was refreshed 24 h later with medium containing just dimethylsulfoxide. When required, 10 mM of a proteasome inhibitor MG-132 (Biomol, Plymouth Meeting, PA, USA) but no siRNA was added 12 h after media was refreshed and cells were cultured for an additional 12 h. A total of 48 h after transfection, cells were lysed to prepare either WCEs for western blotting or total RNA for quantitative PCR.
Raf1 GST-RBD pulldown assay GST-RBD was prepared and pulldown assays performed as described earlier (van Triest et al., 2001) . Briefly, 30 ml of the 50% GST-RBD bead slurry was incubated at 4 1C for 3 h with whole-cell lysates of serum-starved pancreatic cancer cells that had been treated (2 h) with or without the functional Ras inhibitor FTS. To detect specifically bound protein, the beads were washed several times with lysis buffer, boiled in sample buffer and subjected to SDS-polyacrylamide gel electrophoresis and western blotting with anti-K-Ras antibody.
Proliferation assay
Panc-1, Panc-28 or Capan-2 cells were seeded overnight in 96-well plates (3 Â 10 3 cells/well) and treated the next day with inhibitors (Nutlin-3 or PRIMA-1) or transfected as described above with siRNA (control or hdm2). Cells were stained with crystal violet dye and their proliferation was estimated in a Packard plate reader by determining the absorbance (540 nm) as described earlier (Asano et al., 2004) . Each data point was obtained in triplicate, and the averages and standard deviations were estimated.
Quantitative real-time PCR Total RNA was prepared from control and siRNA-transfected cells and reverse transcribed (Reverse Transcription System, Promega, Madison, WI, USA). A real-time quantitative PCR was then performed in an iCycler (Bio-Rad, Hercules, CA, USA) using the iQ SYBR Green Supermix (Bio-Rad) with primers described earlier for the amplification of c-Jun (Kang et al., 2005) , c-Myc (Konnikova et al., 2005) , cyclin D1 (Kang et al., 2005) , GAPDH (Walker et al., 2007) or b-actin (Konnikova et al., 2005) . Reactions were performed in triplicate using the following thermal conditions: activation for one cycle at 95 1C for 30 s; an additional cycle of 95 1C denaturation for 5 min; 40 cycles of denaturation at 95 1C for 30 s, 55 1C annealing for 30 s and 72 1C extension for 30 s; followed by one cycle of 95 1C for 1 min, one cycle at 55 1C for 1 min and 80 cycles of 55-94.5 1C for 10 s.
Transfections and trypan blue exclusion assays HPDE-E6E7 cells were transiently transfected with pCMV or pCMV-hdm2 vector using the Lipofectamine reagent (Invitrogen). After 24 h, whole-cell lysates were probed by western blotting. For other experiments, HA-tagged wild-type c-Jun was excised (HindIII and BglII) from the pSRa-c-Jun plasmid and the fragment blunt-ended before ligation into the SnaBI site of the retroviral expression vector pMX-BGD (Lamothe et al., 2007) . pMX or pMX-c-Jun retroviral supernatants were prepared and used to infect Panc-28 cells as described earlier (Lamothe et al., 2007) . Puromycin-resistant pMX and pMX-cJun stable transfectant pools were propagated and seeded (2.5 Â 10 5 cells/well) in six-well plates. They were then transfected the next day with control or hdm2-1881 siRNA as described above. Although one set of cells were lysed to prepare WCE for western blotting analyses, an identical set of cells were assessed for viability by trypan blue exclusion and counted using a hemacytometer. Student's t-test was used for statistical analysis with Po0.05 taken as the level of significance.
Abbreviations hdm2, human and/or murine double minute-2 protein; MEK, mitogen and extracellular signal-regulated protein kinase; p53, tumor suppressor p53.
